Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold

Jan 6, 2025 · JPMorgan Chase & Co. reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 7.2% during the 3rd quarter, according to its most …

2%
OFF

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold

2 weeks from now

Jan 6, 2025 · JPMorgan Chase & Co. reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 7.2% during the 3rd quarter, according to its most …

marketbeat.com

52%
OFF

Arrowhead Pharmaceuticals Inc, ARWR:NSQ Profile - FT.com

2 weeks from now

Dec 20, 2024 · Year on year Arrowhead Pharmaceuticals Inc 's revenues fell -98.52% from 240.74m to 3.55m. This along with an increase in selling, general and administrative costs has …

ft.com

5%
OFF

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 2.5

2 weeks from now

Jan 6, 2025 · Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report)'s stock price fell 2.5% on Monday . The company traded as low as $19.27 and last traded at $19.30. 89,235 …

marketbeat.com

75%
OFF

Arrowhead Pharmaceuticals (ARWR) P/E Ratio - Public.com

2 weeks from now

The P/E ratio for Arrowhead Pharmaceuticals (ARWR) is -3.78 as of Jan 13, 2025.This represents a decrease of-40.75% compared to its 12-month average P/E ratio of-6.38.A higher P/E ratio …

public.com

$599.49
OFF

Arrowhead Pharmaceuticals (ARWR) Earnings Date And Reports 2025

2 weeks from now

1 day ago · Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a recorded net income of -$599.49 million. ARWR has generated -$5.02 earnings per share over the last four quarters. …

marketbeat.com

2%
OFF

Arrowhead: A Critical Year Ahead That May Reward Patient Investors

2 weeks from now

May 19, 2020 · Turning to Arrowhead's proprietary candidates I assume ARO-AAT and ARO-APOC3 are approved by the end of 2021, with ARO-AAT earning a 2%, 5%, 7.5% and 10% …

seekingalpha.com

13%
OFF

Insiders Sold US$1.6m Of Arrowhead Pharmaceuticals Stock …

2 weeks from now

Nov 27, 2024 · Even though Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stock gained 13% last week, insiders who sold US$1.6m worth of stock over the past year are probably …

simplywall.st

23%
OFF

SRPT Stock Rises 23% In A Year: Time To Buy, Hold Or Sell?

2 weeks from now

Jan 6, 2025 · Shares of Sarepta Therapeutics SRPT have risen 23% in the past year, significantly outperforming the industry’s 15.7% decline, as shown in the chart below. During this …

nasdaq.com

$4125673.52
OFF

Goldman Sachs Reaffirms Their Buy Rating On Arrowhead …

2 weeks from now

Jun 8, 2023 · Last month, Christopher Richard Anzalone, the CEO of ARWR sold 104,928.00 shares for a total of $4,125,673.52. ... Arrowhead Pharmaceuticals, Inc. operates as a …

businessinsider.com

FAQs about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold Coupon?

Should you buy Arrowhead Pharmaceuticals (Arwr – research report)?

In a report released yesterday, Madhu Kumar from Goldman Sachs maintained a Buy rating on Arrowhead Pharmaceuticals ( ARWR – Research Report ), with a price target of $68.00. The company’s shares closed yesterday at $35.70. According to TipRanks, Kumar is a 5-star analyst with an average return of 17.2% and a 51.45% success rate. ...

How much does Arrowhead Pharmaceuticals (Arwr) earn?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a recorded net income of -$205.27 million. ARWR has generated -$1.93 earnings per share over the last four quarters. What is Arrowhead Pharmaceuticals's EPS forecast for next year? ...

Is Arrowhead Pharmaceuticals a good stock to buy?

Currently, the analyst consensus on Arrowhead Pharmaceuticals is a Moderate Buy with an average price target of $59.70, a 67.23% upside from current levels. In a report released on June 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $90.00 price target. The company has a one-year high of $48.48 and a one-year low of $23.09. ...

When did Arrowhead Pharmaceuticals release its quarterly earnings?

Arrowhead Pharmaceuticals last released its quarterly earnings results on November 29th, 2023. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by $0.33. ...

What time does Arrowhead Pharmaceuticals announce financial results?

PASADENA, Calif. -- (BUSINESS WIRE)--Aug. 4, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2022. The company is hosting a conference call today, August 4, 2022, at 4:30 p.m. ET to discuss the results. ...

How much will Arrowhead Pharmaceuticals earn in 2024?

Earnings for Arrowhead Pharmaceuticals are expected to grow in the coming year, from ($3.34) to ($2.97) per share. Arrowhead Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 5th, 2024 based off prior year's report dates. ...